The rise in medication usage for weight loss unlocks opportunities for innovation in health-focused products and ...

There are more than 300 GLP-1Rs in an active stage of development, from industry giants and potential market disrupters.

The FDA has approved Liraglutide Injection, the first generic version of Victoza, for the treatment of type 2 diabetes.

Intuitively, it would seem that GLP-1 use for obesity would reduce overall medical costs despite the increase in drug ...

LBT-3627 is under clinical development by Longevity Biotech and currently in Phase I for Parkinson’s Disease. According to GlobalData, Phase I drugs for Parkinson’s Disease ha ...

New in vivo preclinical data announced today, demonstrate that icovamenib, in combination with semaglutide showed additional 11.5% body weight ...

The "Semaglutides Market Report 2024" report has been added to ResearchAndMarkets.com's offering. This Semaglutides market report covers market characteristics, size and growth, segmentation, regional ...

Kwame Raoul’s office sent cease and desist letters to five unnamed medical spas in the Chicago area that were allegedly ...

Ozempic has fast become a household name. In addition to helping people with diabetes manage their blood sugar levels, this ...

Generic Victoza is a GLP-1 receptor agonist indicated to improve glycemic control in adults and pediatric patients aged 10 ...

Semaglutide biosimilar is under clinical development by Leto Laboratories and currently in Phase II for Diabetes.